

73.1. Thyroid: Differentiated

Authors

R. Michael Tuttle, Lilah F. Morris, Bryan R. Haugen, Jatin P. Shah, Julie A. Sosa, Eric Rohren, Rathan M. Subramaniam, Jennifer L. Hunt, Nancy D. Perrier

Emerging Prognostic Factors for Clinical Care

Impact of Molecular Profiling on Risk Stratification

Tumors harboring *BRAF*, *TERT*, and/or *P53* mutations have the potential to be aggressive, with increased rates of recurrence and disease-specific mortality.¹⁻⁶ Furthermore, *BRAF* V600E mutation appears to increase the risk of disease-specific mortality if identified in conjunction with lymph node metastases, distant metastases, AJCC Stage IV disease, and age ≥ 45 years at diagnosis.⁴ More recent data suggest that tumors harboring multiple oncogenic mutations, although uncommon, may have a more aggressive phenotype.^{5,7} Because many of these mutations are tightly linked to aggressive histologic features, it is difficult to estimate the proportion of risk attributable to the actual mutation versus that attributable to the other clinicopathologic features. Although the 2015 ATA guidelines recognize the potential for improvement in risk stratification with regard to molecular profiling, they do not recommend molecular testing for initial staging because it is not yet clear how much incremental improvement in risk stratification would be gained.⁸

The increased use of more complete, in-depth genomic analyses has led to the discovery of targetable mutations in a small percentage of patients with aggressive thyroid cancers. Recently, promising results were seen with inhibitors of *ALK* fusion genes in medullary⁹ and anaplastic thyroid cancer¹⁰ and with a *BRAF* inhibitor in anaplastic thyroid cancer.^{11,12}

Risk Assessment Models

The AJCC recently established guidelines that will be used to evaluate published statistical prediction models for the purpose of granting endorsement for clinical use.¹³ Although this is a monumental step toward the goal of precision medicine, this work was published only very recently. Therefore, the existing models that have been published or may be in clinical use have not yet been evaluated for this cancer site by the Precision Medicine Core of the AJCC. In the future, the statistical prediction models for this cancer site will be evaluated, and those that meet all AJCC criteria will be endorsed.

Recommendations for Clinical Trial Stratification

The following stratification criteria stem from the prognostic factor analyses suggested for use in thyroid cancer trials, depending on the specific objectives of the study, the cancer stage(s), and the population under study, including sample size:

73.1. Thyroid: Differentiated

- Tumor histology
 - Perineural invasion
 - Multifocality
 - High mitotic index
- AJCC stage
- Age
- Biomarker analysis

The primary stratification for thyroid cancer clinical trials focused primarily on structurally progressive RAI-refractory patient populations will be based on tumor histology, AJCC stage, and age. However, as many of the clinical trial agents are molecularly targeted therapies, risk stratification and data analysis based on biomarker analysis of the tumor may also yield important insights.

Bibliography

1. Melo M, da Rocha AG, Vinagre J, et al. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. *The Journal of clinical endocrinology and metabolism*. 2014;99(5):E754-765.
2. Tufano RP, Teixeira GV, Bishop J, Carson KA, Xing M. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. *Medicine (Baltimore)*. 2012;91(5):274-286.
3. Xing M AA, Carson KA, Shong YK, Kim TY, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, Fagin JA, Puxeddu E, Fugazzola L, Czarniecka A, Jarzab B, O'Neill CJ, Sywak MS, Lam AK, Riesco-Eizaguirre G, Santisteban P, Nakayama H, Clifton-Bligh R, Tallini G, Holt EH, Sykorova V. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. *J Clin Oncol*. 2015;33:42-50.
4. Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. *Jama*. 2013;309(14):1493-1501.
5. Xing M, Liu R, Liu X, et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. *J Clin Oncol*. 2014;32(25):2718-2726.
6. Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. *The Journal of clinical endocrinology and metabolism*. 2005;90(12):6373-6379.

73.1. Thyroid: Differentiated

7. Ricarte-Filho JC, Ryder M, Chitale DA, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. *Cancer Res.* 2009;69(11):4885-4893.
8. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. *Thyroid : official journal of the American Thyroid Association.* 2016;26(1):1-133.
9. Ji JH, Oh YL, Hong M, et al. Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer. *PLoS genetics.* 2015;11(8):e1005467.
10. Godbert Y, Henriques de Figueiredo B, Bonichon F, et al. Remarkable Response to Crizotinib in Woman With Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma. *J Clin Oncol.* 2015;33(20):e84-87.
11. Marten KA, Gudena VK. Use of vemurafenib in anaplastic thyroid carcinoma: a case report. *Cancer Biol Ther.* 2015;16(10):1430-1433.
12. Rosove MH, Peddi PF, Glaspy JA. BRAF V600E inhibition in anaplastic thyroid cancer. *N Engl J Med.* 2013;368(7):684-685.
13. Kattan MW, Hess KR, Amin MB, et al. American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. *CA: a cancer journal for clinicians.* 2016.